| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:(Rac)-BI 703704
CAS:1423067-48-4
Purity:>=95% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
RD International Technology Co., Limited
|
| Tel: |
18024082417 |
| Email: |
market@ubiochem.com |
| Products Intro: |
Product Name:(Rac)-BI 703704
CAS:1423067-48-4
Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:(Rac)-BI 703704
CAS:1423067-48-4
Package:50mg/RMB 24300;25mg/RMB 18300;100mg/RMB 31500
|
|
| | BI 703704 Basic information |
| Product Name: | BI 703704 | | Synonyms: | BI 703704;(Rac)-BI 703704;(Rac)BI 703704,(Rac) BI 703704;3-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[4-[5-methyl-2-[[2-methyl-4-(1-piperidinylcarbonyl)phenyl]methoxy]phenyl]-2-thiazolyl]- | | CAS: | 1423067-48-4 | | MF: | C32H37N3O4S | | MW: | 559.72 | | EINECS: | | | Product Categories: | | | Mol File: | 1423067-48-4.mol |  |
| | BI 703704 Chemical Properties |
| Boiling point | 762.3±70.0 °C(Predicted) | | density | 1.269±0.06 g/cm3(Predicted) | | pka | 4.21±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | BI 703704 Usage And Synthesis |
| Uses | (Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy[1]. | | in vivo | (Rac)-BI 703704 (0.3-10 mg/kg; food intake; daily for 15 weeks) inhibits the progression of diabetic nephropathy in the ZSF1 rat[1]. | Animal Model: | 12-13 weeks male ZSF1 obese rats[1] | | Dosage: | 0.3, 1, 3, or 10 mg/kg | | Administration: | Food intake; daily for 15 weeks | | Result: | Dose-dependent increased in renal cGMP levels; Dosedependent decreased in urinary protein excretion (UPE); Accompanied by a significant reduction in the incidence of glomerulosclerosis and interstitial lesions. |
| | References | [1] Yu L, et al. Picrocrocin exhibits growth inhibitory effects against SKMEL- 2 human malignant melanoma cells by targeting JAK/ STAT5 signaling pathway, cell cycle arrest and mitochondrial mediated apoptosis. J BUON. 2018 Jul-Aug;23(4):1163-1168. PMID:30358226 |
| | BI 703704 Preparation Products And Raw materials |
|